Types of Packaging Material Failures

Common failure modes of packaging materials in stability programs include:

• ❌ Delamination: Separation of laminate layers, especially in foil-based pouches
• ❌ Pinhole or Seal Breach: Resulting in loss of moisture or oxygen barrier
• ❌ High OTR or WVTR: Barrier performance degrades over time or under stress
• ❌ Leachables Migration: Interaction of inks, adhesives, or plastics with the drug product
• ❌ Incompatibility: Between the primary container and the formulation (e.g., sorption, adsorption)

Stability Impact of Packaging Failures

Failure of packaging to maintain critical barriers—such as to moisture, oxygen, or light—can trigger a cascade of stability issues:

• Increased impurity formation due to oxidative stress
• Assay degradation caused by hydrolysis
• Color change and tablet softening in humid environments
• Decreased dissolution performance for film-coated tablets
• Microbial growth in sterile or semi-solid formulations

These problems can manifest during stability studies or post-marketing and lead to OOS results, recalls, or warning letters.

Case Example: Blister Pack Failure in Accelerated Stability

In one documented case, a company used PVC/PE blisters for a moisture-sensitive API. At the 6-month accelerated time point (40°C/75% RH), the assay dropped below 90% and impurities rose above threshold. Investigation revealed inadequate WVTR protection. Upon switching to PVDC-coated PVC, the product passed all subsequent studies. This underscores the role of correct material choice.

Testing Protocols to Detect Material Failures

Pharma companies must implement comprehensive tests for packaging performance, including:

• Seal Integrity: Vacuum decay or dye ingress testing
• Moisture Vapor Transmission Rate (MVTR): ASTM F1249 or USP
• Oxygen Transmission Rate (OTR): ASTM D3985
• Delamination Strength: Measured with peel or tensile tests
• Extractables and Leachables: As per USP and

Regulatory Expectations for Packaging Performance

Regulators expect firms to include data on packaging validation and failure analysis in Module 3.2.P.7 of the CTD:

• ☑ Justification for packaging selection based on product risk
• ☑ Comparative barrier data for alternative packaging
• ☑ Results of packaging qualification studies
• ☑ Risk management outcomes using ICH Q9 principles

Refer to equipment qualification practices when validating packaging lines for sealing consistency.

Root Cause Investigation Framework for Packaging Failures

When failures arise, use structured tools to determine the origin:

• Ishikawa Diagrams: For mapping material, machine, method, and personnel factors
• FMEA: To prioritize risk based on severity and occurrence
• Historical Trending: For identifying patterns in vendor or batch failures

CAPAs should address both immediate causes (e.g., seal temperature) and systemic issues (e.g., inadequate material qualification).

Checklist: Packaging Failure Prevention in Stability Studies

• ☑ Are all packaging components fully qualified and documented?
• ☑ Is WVTR/OTR data consistent with product stability needs?
• ☑ Have integrity tests been conducted across worst-case conditions?
• ☑ Are extractables/leachables studies included in dossier?
• ☑ Are packaging deviations investigated with proper root cause tools?
• ☑ Is there a cross-functional review process for packaging changes?

Conclusion

Packaging material failures can significantly compromise drug product stability and patient safety. Pharma professionals must integrate robust qualification, monitoring, and investigation procedures to ensure packaging consistently protects the drug throughout its shelf life. Regulatory authorities emphasize packaging risk management as a core quality expectation—and failure to meet these can result in serious compliance consequences.

References:

• ICH Q1A(R2): Stability Testing Guidelines
• USP : Containers – Performance Testing
• USP /: Extractables and Leachables
• FDA Guidance for Industry: Container Closure Systems
• EMA Packaging Guidance for Medicinal Products

Case Study 1: Flip-Off Cap Discoloration and Detachment

Product: Parenteral injectable in Type I glass vial with aluminum crimp and flip-off cap

Issue: During 6-month accelerated stability (40°C/75% RH), flip-off caps were found discolored and loosely attached. Further, some caps detached during shipping.

Root Cause: Humidity and thermal stress degraded the internal coating of the aluminum cap, reducing adhesion.

Impact: Stability batch was rejected. Regulatory agency issued a 483 observation for lack of sealing validation under extreme conditions.

Resolution: Caps were upgraded to anodized aluminum with improved lacquer. Thermal cycling and torque validation were added to closure SOP.

Case Study 2: Blister Pack Delamination in Zone IVb

Product: Oral tablet in PVC/PVDC blister with aluminum foil

Issue: Visible delamination occurred in 3 out of 20 blister packs at 30°C/75% RH stability station. Tablets showed signs of moisture exposure.

Root Cause: Inadequate bonding strength between PVC and PVDC layers, aggravated by high humidity.

Impact: Moisture ingress led to tablet softening and color change. Data was not acceptable for submission.

Resolution: Foil specs were revised, and heat sealing parameters were re-validated. A new supplier with proven tropical zone performance was engaged.

Case Study 3: Glass Vial Cracking Post-Autoclave

Product: Aqueous injection in 10 mL Type I glass vial, terminally sterilized

Issue: 5% of vials showed micro-cracks after autoclaving and were flagged during visual inspection at the 3-month stability point.

Root Cause: Thermal expansion mismatch between vial and stopper during steam sterilization.

Impact: Risk of microbial contamination and sterility failure. Entire batch pulled from stability program.

Resolution: Stopper material was changed to a more thermally compatible butyl rubber. Pre-autoclave CCI testing added to QA protocol.

Case Study 4: Label Adhesion Failure Under Humidity

Product: Oral suspension in HDPE bottle with printed label

Issue: Printed labels peeled off at 25°C/60% RH and higher conditions during 12-month stability testing.

Root Cause: Incompatibility of adhesive with bottle surface and environmental conditions.

Impact: Loss of traceability and regulatory non-compliance. WHO audit flagged packaging inadequacy.

Resolution: Switched to wrap-around, pressure-sensitive labels with humidity-resistant adhesive. Packaging SOP was updated to include label adhesion stress testing.

Case Study 5: High Oxygen Ingress in PET Bottles

Product: Vitamin C syrup in PET bottle with screw cap

Issue: Assay of ascorbic acid dropped below 90% within 2 months at 30°C/65% RH stability condition.

Root Cause: PET material had insufficient oxygen barrier properties. Cap was not induction sealed.

Impact: Product failed shelf-life claims and stability protocol was voided.

Resolution: Upgraded to amber glass bottle. Added nitrogen flushing and induction sealing to minimize oxygen exposure.

Case Study 6: Torque Variation and Sealing Defect

Product: Multidose ophthalmic solution in plastic bottle with dropper tip and screw cap

Issue: Leakage observed in several units stored under accelerated stability. Microbial ingress was detected in 2 units.

Root Cause: Improper torque application during capping, causing seal inconsistency

Impact: Potential patient safety risk. Observed by EU inspector during product review.

Resolution: Installed torque monitoring sensors on capping equipment. Line clearance SOP revised to include torque audit at start and end of each shift.

Lessons Learned Across All Case Studies

• Validate packaging materials under all ICH stability conditions, not just long-term storage
• Conduct container closure integrity (CCI) testing pre- and post-storage simulation
• Use extractables and leachables data to proactively assess packaging interactions
• Perform label adhesion, torque, and seal testing as per worst-case transport and humidity exposures
• Include closure vendors in design qualification and documentation activities
• Document all findings in the packaging validation file for regulatory readiness

Regulatory Expectations and Inspection Readiness

According to WHO and ICH Q1A(R2), packaging systems must not alter the product quality, identity, strength, or purity. All changes in closure, label adhesive, or suppliers must be documented with impact assessments. GMP inspections increasingly focus on packaging performance during stability testing, with observations tied to insufficient CCI, torque validation, and component traceability.

How to Strengthen Packaging-Related SOPs

Use real-world cases to update your SOPs for:

• Closure inspection and storage
• Sealing process validation and torque checks
• Label print quality, adhesion, and readability tests
• Environmental simulation of packaging degradation
• CAPA and deviation management for packaging incidents

Refer to pharma SOP templates for examples covering packaging failures and preventive controls.

Conclusion

Packaging failures during stability testing can derail product approvals, compromise safety, and invite regulatory scrutiny. The case studies above demonstrate the wide range of issues that can arise—from humidity-induced label failure to oxygen ingress in plastic bottles. By implementing risk-based design, proactive testing, and robust documentation practices, pharmaceutical companies can avoid these costly errors and ensure compliance with global stability requirements.

References:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• USP : Container Closure Integrity Evaluation
• WHO TRS Guidelines on Packaging and Labeling
• FDA Guidance for Industry: Container Closure Systems
• EU GMP Annex 1 and Annex 15 on Packaging Validation